Healthcare Sector

CCXI

Market Tracker

$10.16
-0.01
(-0.12%)
1:20 pm
Next Earnings: (est.) 03/01/23 12:00 am
  • CCXI (Selected)

    ChemoCentryx, Inc.

CCXI Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

CCXI Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

CCXI Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

CCXI Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

CCXI Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 2.64% 1.88M 97.97M
Vanguard Small-Cap Index Fund 2.27% 1.62M 84.07M
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 2.05% 1.46M 76.14M
iShares Russell 2000 ETF 1.93% 1.37M 71.49M
Vanguard Small-Cap Growth Index Fund 1.34% 954.02k 49.6M
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund 1.02% 728.38k 37.87M
Wasatch Small Cap Growth Fund 0.95% 677.34k 35.22M
Vanguard Extended Market Index Fund 0.92% 654.69k 34.04M
Invesco Small Cap Growth Fund 0.86% 612.49k 31.84M
Wasatch Ultra Growth Fund 0.82% 583.12k 30.32M

CCXI News

  • ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

    10/17 08:30 am

    GlobeNewswire Inc.

    Read more
  • Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

    10/06 09:40 am

    Zacks Investment Research

    Read more
  • ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    10/05 08:30 am

    GlobeNewswire Inc.

    Read more
  • Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

    09/26 06:20 am

    Zacks Investment Research

    Read more
  • Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

    09/23 06:20 am

    Zacks Investment Research

    Read more
  • Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?

    09/08 11:30 am

    Zacks Investment Research

    Read more
  • Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

    09/07 11:30 am

    Zacks Investment Research

    Read more
  • 2 Top Biotech Stocks to Buy for the Long Haul

    08/24 08:40 am

    The Motley Fool

    Read more
  • ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

    08/24 08:30 am

    GlobeNewswire Inc.

    Read more
  • 3 Biopharmas on Buyout Watch

    08/22 08:00 am

    The Motley Fool

    Read more
  • Has Moderna Made a Bear Market Blunder?

    08/17 09:15 am

    The Motley Fool

    Read more
  • Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy

    08/16 12:00 pm

    Zacks Investment Research

    Read more
  • ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?

    08/16 09:55 am

    Zacks Investment Research

    Read more
  • The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

    08/12 06:05 am

    Zacks Investment Research

    Read more
  • Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

    08/11 11:25 am

    Zacks Investment Research

    Read more
  • Get ready for more merger mania in the pharma sector for the rest of the year

    08/11 07:30 am

    MarketWatch

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022

    08/10 10:11 am

    Benzinga

    Read more
  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates

    08/08 05:45 pm

    Zacks Investment Research

    Read more
  • Where ChemoCentryx Stands With Analysts

    08/05 12:02 pm

    Benzinga

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

    08/05 10:43 am

    Benzinga

    Read more
  • 3 Analysts Have This to Say About ChemoCentryx

    08/05 09:48 am

    Benzinga

    Read more
  • Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

    08/05 09:45 am

    Zacks Investment Research

    Read more
  • ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?

    08/05 07:29 am

    Zacks Investment Research

    Read more
  • Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday

    08/05 06:12 am

    Benzinga

    Read more
  • Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday

    08/05 04:00 am

    Benzinga

    Read more
  • Gold Tops 1,800; Alibaba Reports Upbeat Results

    08/04 02:48 pm

    Benzinga

    Read more
  • Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

    08/04 01:12 pm

    Benzinga

    Read more
  • Nasdaq Edges Higher; Crude Oil Falls Sharply

    08/04 12:06 pm

    Benzinga

    Read more
  • Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June

    08/04 10:44 am

    Benzinga

    Read more
  • Why ChemoCentryx Stock Is On Fire Today

    08/04 10:08 am

    The Motley Fool

    Read more
  • Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know

    08/04 10:00 am

    Zacks Investment Research

    Read more
  • ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    08/02 04:05 pm

    GlobeNewswire Inc.

    Read more
  • ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe

    07/05 12:53 pm

    Zacks Investment Research

    Read more
  • ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    07/05 08:30 am

    GlobeNewswire Inc.

    Read more
  • Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?

    06/09 11:30 am

    Zacks Investment Research

    Read more
  • ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

    05/31 04:05 pm

    GlobeNewswire Inc.

    Read more
  • ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa

    05/18 08:30 am

    GlobeNewswire Inc.

    Read more
  • ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference

    05/16 08:30 am

    GlobeNewswire Inc.

    Read more
  • ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis

    05/11 08:30 am

    GlobeNewswire Inc.

    Read more
  • ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates

    05/06 03:38 pm

    Zacks Investment Research

    Read more
  • ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates

    05/05 06:35 pm

    Zacks Investment Research

    Read more
  • Will ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know

    04/28 03:02 pm

    Zacks Investment Research

    Read more
  • ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

    04/13 08:30 am

    GlobeNewswire Inc.

    Read more
  • Why Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report?

    03/31 11:30 am

    Zacks Investment Research

    Read more
  • 2 Stocks Down 30% in 2022 That Are Great Buys Right Now

    03/30 11:30 am

    The Motley Fool

    Read more
  • See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

    03/02 02:51 pm

    Benzinga

    Read more
  • ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates

    03/02 11:33 am

    Zacks Investment Research

    Read more
  • The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

    03/02 08:50 am

    Benzinga

    Read more
  • ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates

    03/01 06:35 pm

    Zacks Investment Research

    Read more
  • The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

    03/01 08:51 am

    Benzinga

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: